Skip to Content
Merck
CN
  • Chronic fluoxetine treatment increases NO bioavailability and calcium-sensitive potassium channels activation in rat mesenteric resistance arteries.

Chronic fluoxetine treatment increases NO bioavailability and calcium-sensitive potassium channels activation in rat mesenteric resistance arteries.

European journal of pharmacology (2015-09-13)
Camila A Pereira, Nathanne S Ferreira, Fabiola L Mestriner, José Antunes-Rodrigues, Paulo R B Evora, Leonardo B M Resstel, Fernando S Carneiro, Rita C Tostes
ABSTRACT

Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), has effects beyond its antidepressant properties, altering, e.g., mechanisms involved in blood pressure and vasomotor tone control. Although many studies have addressed the acute impact of fluoxetine on the cardiovascular system, there is a paucity of information on the chronic vascular effects of this SSRI. We tested the hypothesis that chronic fluoxetine treatment enhances the vascular reactivity to vasodilator stimuli by increasing nitric oxide (NO) signaling and activation of potassium (K+) channels. Wistar rats were divided into two groups: (I) vehicle (water for 21 days) or (II) chronic fluoxetine (10 mg/kg/day in the drinking water for 21 days). Fluoxetine treatment increased endothelium-dependent and independent vasorelaxation (analyzed by mesenteric resistance arteries reactivity) as well as constitutive NO synthase (NOS) activity, phosphorylation of eNOS at Serine1177 and NO production, determined by western blot and fluorescence. On the other hand, fluoxetine treatment did not alter vascular expression of neuronal and inducible NOS or guanylyl cyclase (GC). Arteries from fluoxetine-treated rats exhibited increased relaxation to pinacidil. Increased acetylcholine vasorelaxation was abolished by a calcium-activated K+ channel (KCa) blocker, but not by an inhibitor of KATP channels. On the other hand, vascular responses to Bay 41-2272 and 8-bromo-cGMP were similar between the groups. In conclusion, chronic fluoxetine treatment increases endothelium-dependent and independent relaxation of mesenteric resistance arteries by mechanisms that involve increased eNOS activity, NO generation, and KCa channels activation. These effects may contribute to the cardiovascular effects associated with chronic fluoxetine treatment.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3-[(1R)-1-Hydroxy-2-(methylamino)ethyl]phenol, AldrichCPR
Sodium hydroxide, reagent grade, ≥98%, pellets (anhydrous)
Sodium hydroxide solution, 50% in H2O
Sodium hydroxide, BioUltra, suitable for luminescence, ≥98.0% (T), pellets
Sodium hydroxide, pellets, semiconductor grade, 99.99% trace metals basis
Sodium hydroxide solution, purum, ≥32%
Sodium hydroxide solution, 5.0 M
Sodium hydroxide, reagent grade, 97%, flakes
Sodium hydroxide, ACS reagent, ≥97.0%, pellets
Sodium hydroxide solution, BioUltra, Molecular Biology, 10 M in H2O
Sodium hydroxide, beads, 16-60 mesh, reagent grade, 97%
Sodium hydroxide, reagent grade, 97%, powder
Sodium hydroxide, puriss. p.a., ACS reagent, K ≤0.02%, ≥98.0% (T), pellets
Sodium hydroxide solution, 1.0 N, BioReagent, suitable for cell culture
Sodium hydroxide, puriss., meets analytical specification of Ph. Eur., BP, NF, E524, 98-100.5%, pellets
Sodium hydroxide, BioXtra, ≥98% (acidimetric), pellets (anhydrous)
3-Ethyl-2,4-pentanedione, mixture of tautomers, 98%
Sigma-Aldrich
Diethylenetriaminepentaacetic acid, ≥98% (titration)
Sigma-Aldrich
Diethylenetriaminepentaacetic acid, ≥99% (titration)
Sodium hydroxide, ultra dry, powder or crystals, 99.99% trace metals basis
Sodium hydroxide, puriss. p.a., ACS reagent, reag. Ph. Eur., K ≤0.02%, ≥98%, pellets
Sodium hydroxide, anhydrous, free-flowing, Redi-Dri, reagent grade, ≥98%, pellets
Sodium hydroxide-16O solution, 20 wt. % in H216O, 99.9 atom % 16O